Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sirna Therapeutics Inc.

Division of Alnylam Pharmaceuticals Inc.
www.sirna.com

Latest From Archer Pharmaceuticals Inc.

After Solanezumab, What’s Next? Alzheimer’s Options Take The Stage At CTAD

Lilly will make its first presentation of solanezumab data from the recently failed Phase III EXPEDITION3 study during the Clinical Trials in Alzheimer’s Disease meeting where researchers will discuss amyloid beta and other hypotheses in Alzheimer’s disease Dec. 8-10 in San Diego.

Neurology Clinical Trials

Biomarker study raises hopes for Alzheimer's blood test

Research led by UK company Proteome Sciences and King's College London could lead to a clinical blood test for Alzheimer's disease within five years, and, more immediately, could be helpful in selecting patients for clinical trials of new drugs for the condition. Given the enormous failure rate for drug trials in this indication, it is thought that recruiting patients to drug trials earlier in the disease process before irreversible damage is caused could prove more effective, especially as it is thought that Alzheimer's can be asymptomatic for up to ten years.

Neurology

Discontinuation of iv bapineuzumab places solanezumab under scrutiny

Having failed to meet its co-primary endpoints in the second of four Phase III trials, development of iv bapineuzumab in Alzheimer's disease has been abandoned. Discontinuation of this eagerly anticipated candidate will reignite debate surrounding the appropriateness of targeting beta amyloid in cases where plaques are already present, and shine the spotlight firmly on Lilly's solanezumab, says Datamonitor's Charlotte Mackey.

Neurology Spain

Selected Start-Ups (11/2008)

In Vivo briefly describes these recently founded companies: Archer Pharmaceuticals, Arginetix, Carmat, Catena Pharmaceuticals, EnzymeRX, and P&H Therapeutics.
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ribozyme Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Alnylam Pharmaceuticals Inc.
  • Senior Management
  • Gregory Weaver, SVP, CFO
    Barry Polisky, PhD, SVP, Research & CSO
  • Contact Info
  • Sirna Therapeutics Inc.
    Phone: (415) 512-7200
    1700 Owens St.
    4th Floor
    San Francisco, CA 94158
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register